ArticleNature communications2022
HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 80 citations in OpenAlex.
- Extracellular vesicles in solid tumors: from tumor ecology to engineered therapeutics.Molecular cancer · 2026Review
- The role of small extracellular vesicles in ovarian cancer drug resistance: from bench clues to clinical implications.Journal of ovarian research · 2026Review
- Exosomal nanocarriers of immune fate: molecular insights into cancer immunity, pathogen defense, and emerging immunotherapies.Clinical and experimental immunology · 2026Review
- From immune desert to hot tumor: the tripartite synergy of tumor microenvironment-exosomes-immunogenic cell death in pioneering solutions.Frontiers in immunology · 2026Review
- Exosomes in Clinical Laboratory: From Biomarker Discovery to Diagnostic Implementation.Medicina (Kaunas, Lithuania) · 2025Review
- Turning cold tumors into hot tumors to ignite immunotherapy.Molecular cancer · 2025Review
- Lipid metabolism and lipid signaling in extracellular vesicles ontogeny: from biogenesis to functional execution.Journal of nanobiotechnology · 2025Review
- Munc13-4 mediates tumor immune evasion by regulating the sorting and secretion of PD-L1 via exosomes.Nature communications · 2025Article
- New insights into extracellular vesicles in metastatic cancer: From mechanisms to diagnostics and targeted therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Extracellular vesicles: biogenesis mechanism and impacts on tumor immune microenvironment.Journal of biomedical science · 2025Review
- Mechanical regulation of extracellular vesicle activity during tumour progression.Nature biomedical engineering · 2025Review
- Tumor Microenvironmental Dynamics in Shaping Resistance to Therapeutic Interventions in Melanoma: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors.Nature cancer · 2025Article
- Review
- Extracellular Vesicles and PD-L1-A Review of Complex Immunoregulatory Properties and Clinical Importance.Biomedicines · 2025Review
- Exosome-based immunotherapy in hepatocellular carcinoma.Clinical and experimental medicine · 2025Review
- VPS25 Promotes an Immunosuppressive Microenvironment in Head and Neck Squamous Cell Carcinoma.Biomolecules · 2025Article
- Extracellular vesicles in tumor immunity: mechanisms and novel insights.Molecular cancer · 2025Review
- Biological functions and affected signaling pathways by Long Non-Coding RNAs in the immune system.Non-coding RNA research · 2025Review
- Strontium-Alix interaction enhances exosomal miRNA selectively loading in synovial MSCs for temporomandibular joint osteoarthritis treatment.International journal of oral science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 8 institutions in 2 countries.
Lei Guan *Department of Biology, School of Arts & Sciences, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Bin Wu *Department of Biology, School of Arts & Sciences, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Ting Li *Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Lynn A BeerMolecular & Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA, 19104, USA.
Gaurav SharmaAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Mingyue LiDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Chin Nien LeeDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Shujing LiuDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Changsong YangDepartment of Biology, School of Arts & Sciences, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Lili HuangDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Dennie T FrederickDivision of Medical Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02114, USA.ORCID 0000-0003-3355-5267
Genevieve M BolandDepartment of Surgical Oncology, Massachusetts General Hospital, Boston, MA, MA02114, USA.
Guangcan ShaoNational Institute of Biological Sciences, Beijing, 102206, P. R. China.
Tatyana M SvitkinaDepartment of Biology, School of Arts & Sciences, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0002-8424-447X
Kathy Q CaiHistopathology Facility, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Fangping ChenHistotechnology Facility, The Wistar Institute, Philadelphia, PA, 19104, USA.
Meng-Qiu DongNational Institute of Biological Sciences, Beijing, 102206, P. R. China.ORCID 0000-0002-6094-1182
Gordon B MillsDivision of Oncological Science, School of Medicine and Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97201, USA.ORCID 0000-0002-0144-9614
Lynn M SchuchterAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Giorgos C KarakousisDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Tara C MitchellAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0002-8186-7284
Keith T FlahertyDivision of Medical Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, 02114, USA.ORCID 0000-0002-3402-0478
David W SpeicherMolecular & Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA, 19104, USA.
Youhai H ChenDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0002-9695-6757
Meenhard HerlynMolecular & Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA, 19104, USA.ORCID 0000-0003-0839-0739
Ravi K AmaravadiAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Xiaowei XuDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Wei GuoDepartment of Biology, School of Arts & Sciences, University of Pennsylvania, Philadelphia, PA, 19104, USA. guowei@sas.upenn.edu.ORCID 0000-0002-9251-0360
University of Pennsylvania · USThe Wistar Institute · USHarvard University · USNational Institute of Biological Sciences, Beijing · CNFox Chase Cancer Center · USMassachusetts General Hospital · USOregon Health & Science University · USUniversity of the Arts · US
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3MTumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTargeting exosomal PDL1 to improve immunotherapyP50CA261608 · NCI · WISTAR INSTITUTE · PI VILLANUEVA, JESSIE · 2021 to 2025
$11.3MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MMolecular Basis and Regulatory Mechanisms of Exosome SecretionR35GM141832 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI WEI GUO · 2021 to 2026
$3.9MStructure and functions of the actin cytoskeletonR35GM140832 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Tatyana Svitkina · 2021 to 2026
$2.8MNCI NIH HHS P30 CA010815NCI NIH HHS P30 CA016520NCI NIH HHS P50 CA174523NCI NIH HHS P50 CA261608NIGMS NIH HHS R35 GM140832NIGMS NIH HHS R35 GM141832
Abstract
The lack of tumor infiltration by CD8
Indexed as
ExosomesMelanomaAnimalsB7-H1 AntigenCD8-Positive T-LymphocytesCell Line, TumorHumansImmunotherapyMicePhosphorylationProgrammed Cell Death 1 ReceptorTumor MicroenvironmentB7-H1 AntigenProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.